MEMORIAL HOSPITAL FOR CANCER AND ALL
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $72M
- Transactions
- 2,640
- Companies
- 40
- Average per transaction
- $27,255
Who reported the payments
| Pfizer | $16,117,577 |
| AstraZeneca | $15,753,010 |
| Takeda Pharmaceuticals U.S.A., Inc. | $9,457,417 |
| Array Biopharma Inc | $4,803,859 |
| Adaptive Biotechnologies Corporation | $3,005,793 |
| Bayer | $2,989,495 |
| Merck | $2,157,350 |
| Novartis | $2,066,353 |
| Daiichi Sankyo Company LTD | $1,923,760 |
| Bristol Myers Squibb | $1,676,786 |
| Eisai Inc. | $1,597,473 |
| Astrazeneca UK Limited | $1,498,161 |
| Y-mabs Therapeutics, Inc. | $1,283,539 |
| Plexxikon Inc. | $1,105,247 |
| Biontech SE | $667,390 |
| E.r. Squibb & Sons, L.L.C. | $621,334 |
| Tesaro, Inc. | $518,522 |
| EMD Serono, Inc. | $424,676 |
| CSL Behring | $393,426 |
| Pharmacyclics LLC, An Abbvie Company | $387,537 |
| GE Global Research An Unincorporated Business Of GE Company | $314,966 |
| Siemens Medical Solutions USA, Inc. | $280,114 |
| Janssen Research & Development, LLC | $249,578 |
| Clovis Oncology, Inc. | $230,144 |
| Ipsen Biopharmaceuticals, Inc | $209,451 |
| National Marrow Donor Program | $202,605 |
| Boehringer Ingelheim International GmbH | $200,515 |
| Medivation LLC. | $196,326 |
| Amgen | $193,765 |
| Ventana Medical Systems, Inc. | $171,312 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | $110,149 |
| Mannkind Corporation | $110,103 |
| GE Research | $110,024 |
| Biogen | $104,282 |
| Daiichi Sankyo Inc. | $92,008 |
| Philips North America LLC | $87,600 |
| Intuitive Surgical Operations, Inc. | $74,961 |
| GSK | $72,325 |
| Astellas Pharma Global Development | $71,782 |
| GE HealthCare | $58,819 |